HR Execs on the Move

Shire

www.shire.com

 
At Shire, we enable people with life altering conditions to lead better lives. We focus on developing and delivering innovative treatments for patients with rare diseases and other specialty conditions.To realize our aspiration to become a leading global biotech, our efforts are concentrated on four key strategic drivers: growth, innovation, efficiency, and people. Our priorities are to drive optimal performance of our existing products, increase patient access to these medicines, and to build our pipeline through research and development and partnerships in order to deliver new medicines to patients.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.shire.com
  • 300 Shire Way
    Lexington, MA USA 02421
  • Phone: 617.349.0200

Executives

Name Title Contact Details
Julie Person
 Vice President of Global Talent Management Profile
Megan Sullivan
 Head of Learning and Development Profile
Patricia Robertson
 Head of Learning and Development Innovation and Knowledge Management Profile
Niclas Nordensved
 Head of Learning and Development Profile
Stephanie Engels
 Head of Human Resources Profile

Similar Companies

Capsa Healthcare

Capsa Healthcare, leading provider of medication carts, medical carts, computer carts, wall-mounted work stations & prescription tablet counters.

Osco Drug

Osco Drug is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

encompass clinical research

encompass clinical research is a Spring Valley, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Adjuvants Plus Inc

Adjuvants Plus Inc is a Kingsville, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.